Related Experiment Videos
Risk stratifying acute coronary syndromes: gradient of risk and benefit
1Kerckhoff Clinic and Max-Plank Institute for Clinical and Physiological Research, Bad Nauheim, Germany.
Insights
Cardiac troponins (Troponin T and Troponin I) help identify high-risk patients with unstable angina, improving early risk stratification and treatment decisions for acute coronary syndromes. These sensitive biomarkers detect minimal myocardial injury, guiding therapy and reducing adverse cardiac events.
Area of Science:
- Cardiology
- Biomarkers
- Emergency Medicine
Background:
- Acute coronary syndromes (ACS), including myocardial infarction (MI), have well-understood pathophysiology and established treatments like thrombolysis and antiplatelet therapy.
- Current treatments for ACS reduce morbidity and mortality but carry inherent risks.
- Investigational therapies for unstable angina and non-Q-wave MI include antithrombins and antiplatelet agents.
Purpose of the Study:
- To investigate the role of cardiac troponins (Troponin T and Troponin I) in the early risk stratification of patients with acute coronary syndromes.
- To evaluate the sensitivity and specificity of cardiac troponins in detecting minimal myocardial injury and identifying high-risk patients.
- To explore the utility of cardiac troponins in guiding therapeutic decisions, including the potential benefit from glycoprotein IIb/IIIa receptor inhibitors.
Main Methods:
- Utilizing cardiac troponins (Troponin T and Troponin I) for their high specificity and sensitivity to cardiac muscle.
- Comparing the diagnostic capability of troponins against established markers like CK-MB for detecting microinfarctions.
- Assessing the ability of troponins to identify patients with unstable angina without ST elevations who are at increased risk for cardiac events.
Main Results:
- Cardiac troponins (Troponin T and Troponin I) are more sensitive than CK-MB and can detect microinfarctions in unstable angina patients.
- These biomarkers effectively identify high-risk individuals with unstable angina and without ST elevations, predicting adverse cardiac events like MI and cardiac death.
- Early risk stratification using cardiac troponins in the emergency department facilitates appropriate admission and therapeutic triage decisions.
Conclusions:
- Cardiac troponins are crucial for early risk stratification in acute coronary syndromes, particularly in unstable angina.
- The use of troponins allows for more precise identification of patients who may benefit from specific interventions, such as glycoprotein IIb/IIIa receptor inhibitors.
- Implementing troponin testing in the emergency department can optimize patient management and improve outcomes for acute coronary syndromes.
Abstract:
The pathophysiology of acute coronary syndromes, ranging from unstable angina to non-Q-wave to Q-wave myocardial infarction (MI) has been elucidated over the past 2 to 3 decades. Treatments involving clot lysis and antiplatelet therapy have reduced the morbidity and mortality rates of these syndromes. In patients with persistently elevated ST segments, treatment with thrombolytic agents is well established. In patients with unstable angina and non-Q-wave MI, there is ongoing investigation of the use of antithrombins and antiplatelet agents. Unfortunately, these treatments do not come without risk. The use of cardiac troponins is currently under intensive investigation because of their specificity to cardiac muscle and sensitivity in the determination of minimal myocardial injury. Troponin T and troponin I are more sensitive than CK-MB and are likely able to detect microinfarctions in patients with unstable angina. Most important is the ability of troponin T and troponin I to identify patients with unstable angina without ST elevations who are at high risk for cardiac events, including MI and cardiac death. Early risk stratification in the emergency department with the cardiac troponins allows for more appropriate decisions for admission and therapeutic triage of admitted patients. One such use currently being studied is the ability of the troponins to identify patients who will benefit from glycoprotein IIb/IIIa receptor inhibitors.